In an Aug. 14 press release, medical device company Nu-Med Plus Inc. (NUMD:OTC.MKTS) explained why it believes a recently invalidated patent, which created a monopoly in the market for medical nitric oxide, has "created a very favorable market environment for [its] nitric oxide delivery products."
The company explained that a ruling issued in a federal circuit court in May has "invalidated the majority of a patent for a dominant nitric oxide producer," enabling other medical gas providers to enter the nitric oxide market. With this expansion, "we are ideally positioned to partner with them to sell our delivery systems with their gases," Nu-Med Plus CEO Jeff Robins stated. "The result is a win-win situation for patients and business. As activity in the medical nitric oxide market increases, treatment costs will go down."
Nu-Med Plus is focused on development of "medical applications of newly developed technologies," including delivery equipment for inhaled nitric oxide gas used in the treatment of neonatal hypoxia and pulmonary conditions such as chronic obstructive pulmonary disease (COPD). The company is also investigating "future applications for a variety of other diseases and complications," and maintains its systems offer "portability, a new level of precision [and a] cost-effective method for administrating exacting therapeutic quantities of nitric oxide to patients for a variety of treatments."
Read what other experts are saying about:
Disclosure:
1) Tracy Salcedo compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: Nu-Med Plus. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.
